Berry gene's net profit increased by 50% in the first half of 2018, and the top enterprises continued to lead

August 22, 2018 / Meitong news agency / -- on August 21, 2018, berry gene released its financial performance for the first half of the year ended June 30, 2018 According to the semi annual report, during the reporting period, berry gene achieved sales revenue of 640 million yuan, up 23% year-on-year; net profit attributable to the parent was about 146 million yuan, up 50% over the same period; net cash flow from operations was about 112 million yuan According to the financial report data disclosed in the 2018 half year report of Berea gene, Berea gene's business showed a good momentum of sustained and steady growth in the first half year The major events of Beirui gene in this report period are as follows: 1 Major progress in early diagnosis of tumor: in April, 2018, member enterprises of Beirui gene and Rui gene and National Cancer Science Center jointly launched the clinical early diagnosis test of liver cancer with 10000 people 2 High growth of product model: nextseqcn500 gene sequencer has entered more than 100 hospitals in China 3 Gene big data Industrial Park: the first phase of berry gene data Industrial Park has officially started construction 4 Major upgrade of medical consultation: Professor Shen Yiping from Harvard University Medical School became the chief medical genetic consultant of berry gene, striving to build an international high-end genetic disease consulting team and genetic consulting system 5 Expand gene therapy: the advantage and industry trend of the strategic investment ability of Beret gene to the Faith Medicine of gene therapy drug company drive the business growth of Beret gene business, which is mainly due to the continuous improvement of the company's overall operation ability Beirui gene is the first enterprise to commercialize the non-invasive prenatal screening technology in the world With strong technical strength and commercialization ability, it has established a good reputation in the industry, established a good relationship with customers with high trust, constantly expanded its first mover advantage and always occupied the position of the market leader Another reason is the rapid maturity and continuous development of the whole NIPT industry At present, the domestic NIPT market, valued at 10 billion level, has a market penetration rate of less than 20% In the first half of the year, with the recognition of this innovative technology by clinical medical workers and the awareness of the public, the market demand is increasing day by day, and berry gene seizes the opportunity to make its sales revenue increase substantially The opportunity of scientific research market is not only clinical business With the development of gene sequencing technology, the whole domestic scientific research market has a relatively strong demand for high-quality testing services in 2018 Berry gene seized the opportunity with its strength Berry gene continues to increase investment in scientific research services It not only has a complete and internationally leading high-throughput sequencing platform, but also has established a complete and strict project management and quality management system, which can provide customers with one-stop solutions from solution design, nucleic acid sequencing to biological information analysis At present, berry gene has established stable cooperative relations with more than 80% of hospitals, universities and scientific research institutes in China Layout the whole industrial chain, and prepare to break out in the future As a leading enterprise of gene sequencing, berry gene has made a clear overall plan for the development of gene sequencing industry From cooperating with Illumina in the research and development of nextseqcn500, a second-generation sequencer suitable for clinical detection in China, building a genetic consulting team with international standards, starting to build a big data Industrial Park, to investing in faith companies in gene therapy, the listed berry gene accelerated the overall industrial layout As of June 2018, nextseqcn500 gene sequencer, known as a powerful hospital entry capability, has entered nearly 100 hospitals in China and has successively successfully carried out testing services At the same time, because of the 24-hour technical support of pre-sale, in sale and after-sale provided by these hospitals, bereki ensures that the testing services of each hospital are timely and efficient for patients As a result, berry gene has become one of the few biotech companies in the world that can directly provide technical support for so many hospitals at the same time In the field of genetic disease detection, Professor Shen Yiping, who works in Harvard Medical School, joined berry gene as the chief medical genetic consultant As an influential expert in global genetics and genetic consulting, Professor Shen Yiping will work with berry gene to build a high-quality genetic disease consulting system, which will further promote the construction of consulting standards and systems in China's gene sequencing industry In the field of tumor detection, after the member enterprises and Rui gene obtained the capital increase of 800 million yuan in 2017, in April this year, they jointly launched the liver cancer clinical early diagnosis test with the National Cancer Science Center, marking that China's liver cancer prevention and control has entered the stage of very early prevention and control and clinical verification At the same time, the cancer laboratory got another full mark in the assessment of ngsst of cap, further proving that its medical test has reached the world's top laboratory level In the downstream link, berry gene data Industrial Park has been officially started in April 2018 In the era of precision medicine, gene big data is the key to integrate sequencing and medicine, upstream and downstream In order to make the clinical application of gene detection technology play a greater role, open up a larger market, and achieve the goal of serving human health step by step In addition, based on the synergy of upstream and downstream gene detection, berry gene has made strategic investment in Faith Medicine of gene therapy innovative drug company, which marks that berry gene has further expanded from screening diagnosis based on gene technology to gene therapy For the future, berry gene focuses on the detection of multiple diseases and early diagnosis of tumors With the decrease of sequencing cost and the maturity of technology and market, it will bring more possibilities In this context, the enterprises with independent intellectual property represented by bereki will have more opportunities About the industry leader of gene sequencing of berry gene in the field of clinical transformation Beirui gene (Stock Code: 000710) was founded in May 2010 It is an innovative biotechnology company with global leading high-throughput gene sequencing technology (NGS) It is committed to transforming ngs technology into products and services for improving human health, focusing on three major fields of genetic disease detection, tumor molecular detection and diagnosis, and technology services, and gradually establishing a sequencing platform / product, clinical The industrial chain pattern of bed examination service, full gene database, gene therapy and general population health consultation Beirui gene has developed into a company headquartered in Beijing, covering the whole country and overseas It has established 8 medical laboratories in Shanghai, Qingdao, Chengdu, Chongqing, Fuzhou and other places, established production bases in Hangzhou, established a digital life Industrial Park in Fuzhou, and established Hong Kong yasheneng Gene Technology Co., Ltd in Hong Kong, with more than 1000 employees and market network coverage With more than 2000 hospitals in more than 30 provinces, cities and autonomous regions in China, Gai has become the industry leader in gene detection in the field of clinical transformation, and successfully landed on the A-share main board in August 2017.